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Abstract
Background: Threshold analysis is used to determine the thresh-
old value of an input parameter at which a health care strategy becomes
cost-effective. Typically, it is performed in a deterministic manner, in
which inputs are varied one at a time while the remaining inputs are
each fixed at their mean value. This approach will result in incorrect
threshold values if the cost-effectiveness model is non-linear or if inputs
are correlated.
Objective: To propose a probabilistic method for performing thresh-
old analysis, which accounts for the joint uncertainty in all input pa-
rameters and makes no assumption about the linearity of the cost-
effectiveness model.
Methods: Three methods are compared: (1) deterministic threshold
analysis (DTA); (2) a 2-level Monte Carlo approach, which is consid-
ered to be the gold standard; and (3) a regression-based method using
a Generalised Additive Model (GAM), which identifies threshold val-
ues directly from a probabilistic sensitivity analysis sample.
Results: We applied the three methods to estimate the minimum
probability of hospitalisation for typhoid fever at which three different
vaccination strategies become cost-effective in Uganda. The threshold
probability of hospitalisation at which routine vaccination at 9 months
with catch-up campaign to 5 years becomes cost-effective is estimated
to be 0.060 and 0.061 (95% CI: 0.058-0.064), respectively for 2-level
and GAM. According to DTA, routine vaccination at 9 months with
catch-up campaign to 5 years would never become cost-effective. The
threshold probability at which routine vaccination at 9 months with
catch-up campaign to 15 years becomes cost-effective is estimated to be
0.092 (DTA), 0.074 (2-level), and 0.072 (95% CI: 0.069-0.075) (GAM).
GAM is 430 times faster than the 2-level approach.
Conclusions: When the cost-effectiveness model is non-linear, GAM
provides similar threshold values to the 2-level Monte Carlo approach
and is computationally more efficient. DTA provides incorrect results
and should not be used.
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Background
Health economic evaluations compare two or more alternative courses of
action in terms of costs and consequences. For instance, cost-effectiveness
analyses can evaluate if a new health care strategy is preferred over the
existing strategy (i.e. considering it cost-effective) by comparing costs and
health benefits of the strategies [1]. However, the decisions are often sur-
rounded by considerable uncertainty, which arises from insufficient infor-
mation about important aspects of the disease process and the different
health care strategies under study. The assessment of an uncertain decision
involves expressing how confident we are about the best course of action
given current information, and identifying the most important targets for
information-gathering through new research [2].
Several methods have been developed to characterise the sensitivity and un-
certainty in health care decisions [1]. Traditionally, the impact of parameter
uncertainty has been explored using a deterministic approach. Input pa-
rameter values are varied one at a time, or several at a time, over plausible
ranges to test a model outcome’s responsiveness to these variations [3]. A
special case of deterministic sensitivity analysis is deterministic threshold
analysis (DTA), which determines the input parameter value at which the
preferred health care strategy changes, and is referred to as ’the parameter
threshold value’ [4, 2, 1]. Threshold analysis is typically used to determine
the price at which a health care strategy becomes cost-effective, but it can
also be used, for instance, to determine the minimum disease incidence at
which a health care strategy would be cost-effective in a given setting [5].
Deterministic threshold analysis is straightforward for analysts and easily
understood by decision makers. However, one of the major problems with
only accounting for uncertainty in a deterministic way is that the estimated
cost-effectiveness, and its associated threshold values, can be incorrect in
the case of a non-linear relationship between the input parameters and the
model’s outcomes [1].
Probabilistic sensitivity analysis (PSA) can overcome this limitation [2, 3].
PSA accounts for the plausible values of uncertain input parameters as well
as how likely each of these values are. The result of a PSA can be used to
obtain an unbiased estimate of the expected value of the cost-effectiveness
outcome and a quantification of the uncertainty around this outcome. In ad-
dition, the relationship between the uncertain input parameters and the cor-
responding uncertainty around the cost-effectiveness of a health care strat-
egy can be assessed using a range of statistical methods, including value
of information analysis [6]. McCabe et al. (2020) proposed a probabilistic
threshold analysis based on a 2-level Monte Carlo approach [7]. In com-
plex health economic evaluations, a 2-level Monte Carlo simulation can be
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computationally demanding.
We propose an efficient alternative to DTA, namely a generalised additive
model (GAM), that gives correct threshold values in the case of a non-linear
relationship between inputs and outputs of the health economic model, while
accounting for the uncertainty in all other input parameters. We evaluate
the accuracy and computational efficiency of GAM in estimating threshold
values by comparing it with the 2-level Monte Carlo probabilistic threshold
analysis. Our working example is a recent peer-reviewed health economic
evaluation of vaccination against typhoid fever. In this example, there is
a non-linear relationship between the uncertain input parameters and the
corresponding cost-effectiveness of the typhoid vaccination program, which
is due in part to the use of a dynamic transmission model [8].
Methods
Net benefit as measure for cost-effectiveness
A health economic evaluation compares the costs and health effects (such
as deaths or disability-adjusted life-years (DALYs) averted) of alternative
courses of action (including ’current practice’). As such, it informs decision
makers about the relative efficiency of a change in policy (for example, the
adoption of a new policy option). The relative efficiency of one policy option
versus another is usually expressed as an incremental cost-effectiveness ratio
(ICER) or as an incremental net monetary (or health) benefit. Throughout
this paper, we use incremental net monetary benefit (INB) as the measure
of cost-effectiveness so that the threshold methods we propose are general
applicable. Indeed, when uncertainty is accounted for in a probabilistic
way, the expected ICER is only interpretable when comparing two decision
options (e.g. new strategy versus current strategy) and when all incremental
costs and effects are positive [9]. The INB is defined as:
INBd = λ∆Ed −∆Cd
= λ(Ed − Ed0)− (Cd − Cd0) (1)
where INBd represents the incremental net benefit for option d (d = 1, . . . , D),
one of D alternative health care strategies under consideration, relative
to the baseline strategy, d0; λ represents the decision maker’s maximum
willingness-to-pay (WTP) per unit gain in health; ∆Ed is the incremental
health benefit of option d compared to the baseline strategy; and ∆Cd is
the difference in costs between strategy d and the baseline strategy. The
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optimal health care strategy is that which has the highest INB [10, 9, 1].
The current strategy is typically chosen as the baseline strategy, but any
strategy can be chosen, as long as the same baseline strategy is chosen for
all options compared.
Usually, there is considerable uncertainty around the expected values of in-
put parameters due to limited evidence on the expected costs and effects of a
health care strategy d. Therefore, the expected INBd will also be surrounded
with uncertainty. We account for this uncertainty by assigning appropriate
probability distributions to the input parameters (θ), denoted by p(θ) [1].
We sampleK values from p(θ), and calculate theK corresponding INBd val-
ues. The most cost-effective strategy is the strategy with highest expected
incremental net benefit. We adapt equation 1:
Eθ[INBd(θ)] ≃
1
K
K∑
k=1
{
λ(E
(k)
d − E
(k)
d0
)− (C
(k)
d − C
(k)
d0
)
}
(2)
where Eθ[INBd(θ)] denotes the expected INB of health care strategy d based
on distribution of all parameters.
Definition of threshold value
The threshold value for a parameter θi, is the value θ
∗
i for which the following
two conditions hold:
1. We can identify decision options, d′ and d′′, where d′ 6= d′′, that have
expected net benefits, conditional on θi, that are equal, i.e.
Eθ−i|θi [INBd′(θi,θ−i)] = Eθ−i|θi [INBd′′(θi,θ−i)] (3)
2. There must be no decision option with expected net benefit, condi-
tional on θi, that is greater than that for d
′, i.e.
Eθ−i|θi [INBd′(θi,θ−i)] ≥ Eθ−i|θi [INBd(θi,θ−i)] (4)
for all d.
where θi, in equation 3 and 4, has an appropriate probability distribution
(p(θi)) to characterise its uncertainty. The first condition determines that
θ∗i is a value for which decision option d
′ has the same conditional expected
net benefit as option d′′ and is therefore a threshold value, and the second
condition determines that θ∗i is a threshold value where the optimal health
care strategy changes. Determining the threshold value, θ∗i , in the net benefit
framework leads to a dependence between θ∗i and the chosen WTP value, λ.
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Deterministic threshold analysis
Deterministic threshold analysis seeks to identify the value of a parameter for
which the optimal health care strategy changes, while keeping all other input
parameters constant. More formally, the deterministic parameter threshold
value (θ∗i ), must satisfy two conditions:
1. θi is the parameter for which we can identify policy options, d
′ and d′′,
where d′ 6= d′′, that have INB, conditional on θi, that are equal, i.e.
INBd′(θi,E[θ−i]) = INBd′′(θi,E[θ−i]) (5)
2. There must be no decision option with net benefit (conditional on θi)
greater than that for d′, i.e.
INBd′(θi,E[θ−i]) ≥ INBd′′(θi,E[θ−i]) (6)
for all d.
where θi, in equation 5 and 6, refers to point estimates. The first condition
determines that θ∗i is a parameter value where decision option d
′ has the
same INB (evaluated at the mean values of θ−i) as option d
′′, and the
second condition determines that θ∗i is a threshold value, where the optimal
health care strategy changes to d′. Again, the threshold value, θ∗i depends
on the chosen WTP value, λ, in the net benefit framework.
The analysis proceeds as follows [11, 12]:
1. Define the uncertain parameter of interest, θi.
2. Fix remaining input parameters θ
−i (i 6= −i) at their expected values.
3. The threshold value θ∗i can be obtained in the following ways:
(a) Graphically: Vary the values θi (generally 5-10 different values)
and assess the impact on the cost-effectiveness (e.g. plot INBd
for each health care strategy d relative to a baseline option d = 0
as a function of the different values of the uncertain parameter of
interest); the point at which any of the top two lines cross is θ∗i .
(b) Algebraically: Solve the linear system composed of two health
economic models, one for d′ and the other for d′′, to find θ∗i satis-
fying equation 5 and 6. Solve the linear system for any combina-
tion of d′ and d′′. Make sure that θ∗i is obtained within the range
of plausible values of θi.
(c) Numerically:
i. Vary over K (k = 1, . . . ,K) values of θi and record the cor-
responding INBd, for each d.
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ii. Sort the values of INBd, for each d, according to ascending
θi values;
iii. Set INB
(k)
d = 0 for the ’baseline’ decision option d=0;
iv. Determine the health care strategy with the highest INBd for
θ
(k)
i , d
(k) = argmaxd INB
(k)
d ;
v. Determine any value, k∗, such that d(k
∗) 6= d(k
∗+1);
vi. Each k∗ will define a threshold value θ∗i that lies in the in-
terval θ
(k∗)
i < θ
∗
i < θ
(k∗+1)
i (see note);
Note: There may be no values of k∗, in which case there are no
threshold values, and the optimal health care strategy does not
depend on the value of the input parameter θi considered. Or
there may be a single value of k∗, in which case there is a single
threshold value, θ∗i . Since the closest we can get to θ
∗
i is, θ
(k∗)
i
or θ
(k∗+1)
i we approximate θ
∗
i by the upper bound of the interval.
This is justified as long as sufficient values are sampled from the
distribution of θi.
If the cost-effectiveness measure (INBd) has a non-linear relationship with
the input parameters θ−i, then
Eθ−i|θi [INBd(θi,θ−i)] 6= INBd(θi,E[θ−i]). (7)
Consequently, a deterministic threshold analysis will result in an incorrect
estimate of the threshold value θ∗i [13].
Probabilistic parameter threshold analysis
When a deterministic threshold analysis results in incorrect estimates for θ∗i ,
one can rely on a probabilistic parameter threshold analysis. The advantage
of a probabilistic parameter threshold analysis is that it incorporates the
joint uncertainty in all parameters, resulting in the correct estimation of
θ∗i even when non-linear relationships exist between INBd and θ−i. The
key to finding the value θ∗i that satisfies the conditions (3) and (4) lies in
finding a way to estimate Eθ−i|θi [INBd(θi,θ−i)]. The most obvious way to
do this is via Monte Carlo sampling, but this leads to a ‘nested’ 2-level
scheme in which values of θi are sampled in an outer loop, and conditional
on this, values of θ−i are sampled in an inner loop. The existing 2-level
Monte Carlo approach is computationally costly, therefore we propose an
alternative method to estimate Eθ−i|θi [INBd(θi,θ−i)] using a non-parametric
regression-based method, called a generalised additive model (GAM), first
proposed by Strong et al. (2014) [14].
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2-level Monte Carlo approach
We can estimate the term Eθ−i|θi [INBd(θi,θ−i)] in Equations (3) and (4)
using a 2-level Monte Carlo approach. A detailed overview of the approach
is given in Algorithm 1.
Algorithm 1: 2-level Monte Carlo scheme for estimating threshold value
θ∗i for parameter θi
1 Sample K times from the distribution of the parameter of interest p(θi);
2 Order sampled values such that θ
(1)
i < θ
(2)
i < . . . < θ
(K−1)
i < θ
(K)
i ;
3 for k = 1 to K do
4 for j = 1 to J do
5 Sample θ
(j,k)
−i from the conditional distribution of the remaining
parameters, p(θ−i|θ
(k)
i )(the same parameter uncertainty
distributions are assumed as in PSA);
6 Evaluate the incremental net benefit function for each d and
store INBd(θ
(k)
i ,θ
(j,k)
−i );
7 end
8 Compute and store inner loop mean for each of the alternative
strategies d = 1, . . . , D, INB
(k)
d =
1
J
∑J
j=1 INBd(θ
(k)
i ,θ
(j,k)
−i ). These
are estimates of the conditional expected value
Eθ
−i|θi [INBd(θ
(k)
i ,θ−i)];
9 Set INB
(k)
d = 0 for the ‘baseline’ decision option d = 0;
10 Determine the policy option with the highest expected INB given
θ
(k)
i , d
(k) = argmaxd INB
(k)
d ;
11 end
12 Determine any value(s), k∗, such that d(k
∗) 6= d(k
∗+1) (see note);
13 Each k∗ will define a threshold value θ∗i that lies in the interval
θ
(k∗)
i < θ
∗
i < θ
(k∗+1)
i ;
Note: There may be no values of k∗, in which case there are no threshold
values, and the optimal health care strategy does not depend on the value
of the input parameter θi considered. There may be a single value of k
∗, in
which case there is a single threshold value, θ∗i . Or, there may be multiple
values of k∗ and therefore multiple threshold values. We approximate θ∗i
by the midpoint of the interval
{
θ
(k∗)
i , θ
(k∗+1)
i
}
. This is justified as long as
sufficient values are sampled from the distribution of θi.
This approach is very computationally intensive for all models except for
very simple models due to the need to evaluate the incremental net benefit
function K × J times [14, 15, 16]. Ideally, K should span the range of
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the parameter of interest θi and K and J should be large. In practice, a
stepwise approach can be used to determine the area of the input parameter
(outer loop) containing the threshold value. Indeed, due to the complexity
of the chosen health economic evaluation (section ’A real-world example’),
we were only able to sample seven values from p(θi) (K = 7) in order to keep
J large (J = 10000). At first, we used a broad range of θi and narrowed
the range until we had a precise (up to three decimals) parameter threshold
value. Since we only performed a limited number of outer iterations, we
refer to this approach as the adjusted 2-level Monte Carlo approach. Lastly,
we recommend the values of J be varied until a stable θ∗i is obtained.
Regression-based approach using a generalised additive model
As an alternative to the 2-level Monte Carlo approach, we propose a meta-
model approach, based on a GAM, summarising the relationship between
the inputs and the outputs post-simulation. This regression-based approach
only requires the PSA sample to correctly estimate θ∗i while satisfying the
conditions in (3) and (4).
A GAM allows for flexible specification of the relationship between the INBd
and the input parameters θ for each health care strategy under consider-
ation. Hence, detailed parametric specifications are not needed. First, we
define the PSA sample as a set of K samples from the joint distribution of
the model input parameters, {θ1, . . . ,θK}, and the corresponding evalua-
tions of the INB function {INBd(θ
1), . . . , INBd(θ
K)} for each health care
strategy d = 1, . . . , D compared to a baseline option d0. In general, a GAM
is defined as follows:
INBd(θ
k
i ) = Eθ−i|θki
[INBd(θ
k
i ,θ−i)] + ǫ
k (8)
= gd(θ
k
i ) + ǫ
k (9)
where equation (8) expresses the INBd as the sum of the conditional expecta-
tion we require, and a mean-zero error term ǫ, and equation (9) re-expresses
the conditional expectation as an unknown function of θi. See Strong et al.
(2014) for a detailed derivation [14].
We do not know the form of the unknown function gd(θi), but we do expect
it to be smooth, so we choose to model it using a GAM. Different choices
can be made for the smooth function s(·) (equation 10), but a typical choice
is a third order polynomial spline. A third order polynomial spline is a curve
constructed from sections of cubic polynomials that are joined together end-
to-end at a series of ‘knots’. Any cubic spline can also be represented by
the weighted sum of a series of ‘basis’ functions (in the same way that any
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sound wave can be constructed from the sum of a series of sine waves of
different frequencies) Thus, we can write:
gd(θi) = s(θi) =
L∑
l=1
βlbl(θi), (10)
where bl(·) are basis functions, with corresponding weights βl that are es-
timated from the data. The value L and smoothing parameter control the
model’s smoothness. The latter adds a penalty to the likelihood of the spline
to suppress overly flexible terms. In the implementation of the GAM in the
mgcv package in R, the optimal penalty is by default learnt from the data us-
ing cross-validation, while the value L must be pre-chosen and is fixed to be
large [17]. In our example, we chose cubic regression splines with dimension
20 and smoothing parameter obtained using cross-validation to model the
data. We obtained the basis and the dimension after a sensitivity analysis.
Changing both the basis and the dimension did not influence the threshold
value. Therefore, we opted for a combination of basis and dimension that
provided a stable threshold value and was not too computationally demand-
ing at the same time (for a detailed overview see Appendix C). For a more
extended explanation on GAMs, we refer to [17, 14].
We propose the following algorithm to obtain the parameter threshold value,
θ∗i , using a GAM:
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Algorithm 2: Regression-based scheme for estimating threshold value
θ∗i for parameter θi.
1 Sample K times from the joint distribution of all parameters p(θ);
2 Order sampled values of θ with respect to θi such that
θ
(1)
i < θ
(2)
i < . . . < θ
(K−1)
i < θ
(K)
i ;
3 for k = 1 to K do
4 Evaluate the incremental net benefit function for each d and store
INBd(θ
(k)). This is the standard ‘PSA’ sample;
5 end
6 for d = 1 to D do
7 Regress INBd(θ
(1,...,K)) on θ
(1,...,K)
i using a GAM (R code available
in Appendix A);
8 Compute the regression fitted values, ÎNB
(1,...,K)
d . These are
estimates of the conditional expected values
Eθ
−i|θi [INBd(θ
(1,...,K)
i ,θ−i)];
9 end
10 for k = 1 to K do
11 Set ÎNB
(k)
d = 0 for the ‘baseline’ decision option d = 0;
12 Determine the policy option with the highest expected INB given
θ
(k)
i , d
(k) = argmaxd ÎNB
(k)
d ;
13 end
14 Determine any value(s), k∗, such that d(k
∗) 6= d(k
∗+1) (see note);
15 Each k∗ will define a threshold value θ∗i that lies in the interval
θ
(k∗)
i < θ
∗
i < θ
(k∗+1)
i (A function, written in R [18], is available in
Appendix A);
Note: There may be no values of k∗, in which case there are no threshold
values. There may be a single value of k∗, in which case there is a single
threshold value, θ∗i . Or, there may be multiple values of k
∗ and therefore
multiple threshold values. We approximate θ∗i by the midpoint of the inter-
val
{
θ
(k∗)
i , θ
(k∗+1)
i
}
.
Quantification of uncertainty
We use a bootstrap procedure to provide a measure of precision and ac-
curacy of the parameter threshold value in the presence of possible model
violations. We opted for a non-parametric bootstrap because it does not rely
on asymptotic normality and hence will be applicable for a wider range of ap-
plications. If asymptotic normality holds, Strong et al. (2014) [14] described
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a method to obtain the standard errors directly from the GAM. The non-
parametric bootstrap relies on sampling with replacement from the observed
PSA sample {θ, INB}. We sample B times from the PSA sample, generat-
ing b = 1, . . . , B bootstrap sampled versions of the PSA sample {θb, INBb}.
For each of the bootstrap samples, the parameter threshold value, θ∗b, is cal-
culated using algorithm 2. The uncertainty about the threshold value can
then be expressed through a (1−α)% interval from θ∗(α/2) to θ
∗
(1−α/2) where
θ∗(α/2) represents the α/2 percentile of the bootstrap values θ
∗b [19, 20].
Depending on the bootstrap sample, a different number of parameter thresh-
old values might arise compared to the original PSA sample, in particular
when the input parameter does not influence the cost-effective strategy (i.e.
low EVPPI value). To acknowledge this type of uncertainty about the num-
ber of threshold values, we denoted the number of bootstrap samples result-
ing in the same number of threshold values as the original PSA sample as
Bretain. The lower Bretain, the more uncertainty there is about the number
of threshold values. If a bootstrap sample produces a different number of
threshold values than the original PSA sample, then this bootstrap sample
is discarded before calculating the bootstrap uncertainty interval.
A real-world example
We chose a health economic evaluation comparing typhoid conjugate vacci-
nation strategies in Gavi-eligible countries as a real-world example, in which
there is a non-linear and even non-monotone relationship between some of
the uncertain input parameters and the corresponding cost-effectiveness of
the typhoid vaccination program. This example allowed us to illustrate the
various possible outcomes of threshold analysis. The health economic eval-
uation aimed to inform decision makers on the cost-effectiveness of three
different vaccination strategies compared to each other and to no vaccina-
tion (no vac; d0): routine vaccination of infants at 9 months of age, or
routine vaccination at 9 months with a catch-up campaign up to either 5
years (RC5) or 15 years of age (RC15). In this paper, threshold values
were determined for an evaluation comparing only two health care strate-
gies (vaccination strategy RC15 compared to the baseline option (no vac)),
and for an evaluation comparing three health care strategies (vaccination
strategies RC5 and RC15 versus the baseline option (no vac)), since routine
vaccination without catch-up was never the optimal strategy in the original
analysis [8].
We chose to obtain threshold values for uncertain input parameters for
three countries (Nicaragua, Uganda, and Cambodia), assuming WTP values
per DALY averted that allowed us to illustrate different possible outcomes
12
(no threshold value, a single threshold value, and more than one threshold
value).
We assessed parameter threshold values for three uncertain input parame-
ters: typhoid case fatality ratio when hospitalised (CFRhosp), the probabil-
ity of hospitalisation for typhoid fever (Pr(hosp)), and the duration of illness
for patients seeking medical care (DOIcare) (Table 1). The case fatality ratio
and probability of hospitalisation were chosen because in some settings they
had a had a non-linear, respectively non-monotone relationship with the
cost-effectiveness outcome and had a big impact on the optimal health care
strategy (i.e. they had the highest expected value of obtaining perfect infor-
mation (EVPPI)), for the countries and WTP values we considered. Hence
threshold values for these parameters informed changes to the optimal strat-
egy. The parameter duration of illness was chosen because it had a much
lower EVPPI value for the countries and WTP values considered, hence less
impact on the optimal strategy. This parameter was chosen to illustrate the
performance of the different threshold methods when a threshold value was
not necessarily expected.
Table 1: Distributional characteristics of the uncertain input parameters.
Parameter Mean Median 95% CIa Uncertainty distribution
CFRhosp 0.059 0.044 0.008-0.196 logit
−1(N(−3.07, 0.87)
Pr(hosp) 0.061 0.038 0.004-0.249 logit−1(N(−3.25, 1.20)
DOIcare (years) 0.043 0.043 0.034-0.054 Gamma(16, 2)/365
a 95% credible interval.
Table 1 shows the uncertainty distributions for the three input parame-
ters considered in this paper. the uncertainty distributions around the ex-
pected case fatality ratio and probability for hospitalisation are right skewed.
Their means and standard errors are estimated from a random-effects meta-
analysis. As a consequence of the logistic regression model, the standard
errors are only available on the logit scale. After sampling from the normal
distribution on the logit scale, the values are transformed to their original
scale using the inverse logit ( e
x
1+ex ). The mean and standard error ofDOIcare
are also estimated using a random-effects meta-analysis. Since, DOIcare is
Poisson distributed, we sample from a Gamma distribution. The sampled
values are rescaled such that DOIcare is expressed in years [8].
Results
The appropriate method to perform threshold analysis depends on the fea-
tures of the health economic model. Figure 1 presents a flowchart describ-
ing the most suitable method to carry out parameter threshold analysis. A
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GAM would be the most suitable method to obtain parameter threshold
values in our example due to the non-linear relationship between the uncer-
tain input parameters and INBd. However, we perform all three methods:
a deterministic threshold analysis, an adjusted 2-level Monte Carlo method,
and a GAM, to compare the threshold value(s) obtained by each method.
Table 2 shows the parameter threshold values for different scenarios. We
kept the size of the samples equal in all scenarios and for all input parame-
ters (K = 10000 for GAM and deterministic threshold analysis, K = 7 and
J = 10000 for the adjusted 2-level Monte Carlo analysis). The same holds
for the number of values for K that were used in the adjusted 2-level Monte
Carlo approach (K = 7) (Appendix B).
Figure 1: A guide for performing parameter threshold analysis.
Deterministic threshold analysis is computationally faster than the adjusted
2-level Monte Carlo approach, but slower than GAM. In this example, it
consistently overestimates the value of θ∗i , i.e. it overestimates the minimum
value at which a vaccination strategy is preferred over no vaccination. Where
the adjusted 2-level Monte Carlo approach and GAM result in two parameter
threshold values, deterministic threshold analysis is only able to obtain one.
According to the deterministic threshold analysis, RC5 will never be the
optimal health care strategy.
GAM is able to calculate the threshold value(s) in a fraction of the time
that is needed for the adjusted 2-level Monte Carlo approach. Although
the bootstrap procedure is time consuming, GAM is still faster than the
adjusted 2-level Monte Carlo approach.
There is a good agreement between GAM and the adjusted 2-level Monte
Carlo approach. In most settings, the two approaches provide a parameter
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Table 2: A comparison of the parameter threshold values obtained with deterministic threshold analysis (DTA), adjusted
2-level Monte Carlo (MC) approach, and GAM for different settings.
DTA Adjusted 2-level MC GAM
K = 10000 K = 7, J = 10000 Cubic regression splines, L = 20, K = 10000
θi EVPPI θ
∗
i d
(k∗+1) Timea θ∗i d
(k∗+1) Timea θ∗i d
(k∗+1) Timea 95% CI Bretain/B Time
b
Nicaragua, WTP = $1000, 1 health care strategy (D = 1; RC15) compared to no vaccination (d0)
CFRhosp 700094 0.062 RC15 16.6 0.040 RC15 235.6 0.036 RC15 0.6 0.035-0.039 998/1000 159.5
Pr(hosp) 1276475 0.052 RC15 14.4 0.043 RC15 220.0 0.041 RC15 0.6 0.040-0.043 1000/1000 160.2
DOIcare 0 Nonec No vac 14.6 None RC15 231.0 None RC15 0.5 NA-NA 391/1000 159.2
Nicaragua, WTP = $1000, 2 health care strategies (D = 2; RC5 and RC15) compared to no vaccination (d0)
CFRhosp 1860599 0.113 RC15 15.9 0.069 RC15 219.2 0.064 RC15 0.7 0.060-0.071 983/1000 199.1
Pr(hosp) 2665148 0.093 RC15 14.5 0.074 RC15 207.7 0.070 RC15 0.6 0.066-0.073 1000/1000 189.9
DOIcare 0 None No vac 16.7 None No vac 214.3 None No vac 0.6 NA-NA 191/1000 189.6
Uganda, WTP = $800, 2 health care strategies (D = 2; RC5 and RC15) compared to no vaccination (d0)
CFRhosp 18451230 0.109 RC15 23.3 0.056 RC5 241.0 0.058 RC5 0.6 0.052-0.061 965/1000 199.2
0.070 RC15 0.071 RC15 0.065-0.076
Pr(hosp) 25018120 0.092 RC15 14.9 0.060 RC5 214.8 0.061 RC5 0.6 0.058-0.064 999/1000 194.5
0.074 RC15 0.072 RC15 0.069-0.075
DOIcare 4256 None No vac 14.9 None RC5 217.3 0.033 RC5 0.7 0.030-0.061 98/1000 202.1
Cambodia, WTP = $100, 2 health care strategies (D = 2; RC5 and RC15) compared to no vaccination (d0)
CFRhosp 2788364 0.114 RC15 16.8 0.053 RC5 227.5 0.055 RC5 0.6 0.052-0.062 955/1000 188.9
0.080 RC15 0.083 RC15 0.076-0.091
Pr(hosp) 4837512 0.083 RC15 16.5 0.059 RC5 226.8 0.060 RC5 0.7 0.058-0.062 998/1000 191.4
0.083 RC15 0.085 RC15 0.081-0.090
Cambodia, WTP = $8000, 2 health care strategies (D = 2; RC5 and RC15) compared to no vaccination (d0)
CFRhosp 0 None RC15 13.7 None RC15 219.1 None RC15 0.6 NA-NA 966/1000 188.5
Pr(hosp) 0 None RC15 14.5 None RC15 218.6 None RC15 0.6 NA-NA 714/1000 198.4
Notation: θi = parameter of interest; θ
∗
i = threshold value(s), if present, for θi; d
(k∗+1) = health care strategy with the highest
expected INB at θ
(k∗+1)
i . If not mentioned otherwise, the health care strategy at d
k∗ is no vaccination; Bretain= number of bootstrap
samples retained to calculate the 95% confidence interval (CI); EVPPI= Expected value of partial perfect information. It quantifies the
value of obtaining perfect information on the parameter of interest. The EVPPI is calculated based on Strong et al. (2014) [14]; WTP=
willingness-to-pay for one disability-adjusted life-year averted (in USD); No vac= no vaccination; RC5= routine vaccination with
catch-up campaign to 5 years; RC15= routine vaccination with catch-up campaign up 15 years. a,b indicate the time needed to perform
respectively the method and the bootstrap, (GAM: excluding the time needed to obtain the PSA sample). c ’None’ indicates that no
parameter threshold value was obtained, meaning that the health care strategy with the highest expected INB remains the same and is
denoted under d(k
∗+1).
threshold value that is precise up to two decimals, with the exception of the
input parameterDOIcare in Uganda. In Uganda (WTP = $800, D = 2), the
adjusted 2-level Monte Carlo approach shows no parameter threshold value,
whereas GAM does suggest a threshold value; however, the 95% CI of the
threshold DOIcare in the GAM approach spans almost the entire range of
possible values for that parameter, indicating a lot of uncertainty about the
parameter threshold value. The proportion of bootstrap samples retained
was low for DOIcare in Nicaragua and Uganda, indicating uncertainty about
whether and how many threshold values could be identified. Therefore,
we do not recommend to interpret threshold values when the number of
bootstrap samples retained is low. For more technical details, see Appendix
D.
For Cambodia, we considered two different WTP values, $100 and $8000.
When we considered a WTP value of $100, both the adjusted 2-level Monte
Carlo approach and GAM find two threshold values. For the higher WTP
value, no parameter threshold values are found. This was expected, since
the EVPPI was low at the higher WTP value.
Discussion
We propose GAM as a novel regression-based approach to calculate a pa-
rameter’s threshold value(s) in health economic evaluations. The GAM ap-
proach only requires the PSA sample of a cost-effectiveness analysis, is flex-
ible, easy to use, and computationally efficient. In our example, GAM does
not provide incorrect threshold values or fails to find threshold values (as
the deterministic approach does). GAM also outperforms the 2-level Monte
Carlo approach in terms of computational time.
GAM has several advantages over the existing methods. Firstly, GAM re-
sults in the same threshold values as the adjusted 2-level Monte Carlo ap-
proach when cost-effectiveness measures are non-linearly related to the in-
puts, unlike the deterministic threshold analysis. Our example (Table 2)
showed that threshold values were overestimated and that not all threshold
values were identified with the deterministic threshold approach. Therefore,
threshold values obtained from a deterministic threshold analysis should not
be interpreted when there is a non-linear relationship between inputs and
outputs. Secondly, GAM is easy to use because it relies on the PSA sample
to account for uncertainty in the input parameters’ distribution, there is no
need to assume plausible values as in the deterministic threshold approach
[21]. Thirdly, GAM is computationally fast compared to the 2-level Monte
Carlo approach. In order to perform the 2-level Monte Carlo approach, we
needed at least 210 seconds for K = 7. The time needed to perform a
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GAM, including the bootstrap procedure, was at most 189 seconds (Table
2). Lastly, threshold values obtained by GAM were quite robust against
changes in dimension and the smoothing function chosen (Appendix C).
There are some limitations of this work. Firstly, we only performed the com-
parison of the three threshold approaches on one example. However, this
proved to be sufficient to show the incorrectness in the deterministic thresh-
old values. Secondly, we were limited in the number of samples we could use
in the 2-level Monte Carlo approach because running our health economic
evaluation was computationally too intensive. Thus, we could not perform a
complete 2-level Monte Carlo method on a normal personal computer. The
focus of this article was not to optimise the 2-level Monte Carlo method, but
rather to use it as a comparison for the alternatively proposed GAMmethod.
Complex evaluations including dynamic transmission models, numerous in-
tervention options, multiple countries, and considering a long time horizon
will become more common in the future. This in itself is an important rea-
son for using GAM. But increasing the computational efficiency of complex
models will also be helpful here. Third, although we use bootstrapping to
provide a measure of uncertainty about the threshold value (and therefore
avoid making assumptions of normality and homoscedasticity of the regres-
sion residuals), the non-parametric bootstrap itself has a limitation due to
the nature of the statistic we are interested in. Due to sampling with re-
placement, it is possible that more or fewer parameter threshold values arise
compared to the number obtained from the original PSA sample.
Parameter threshold analysis provides a useful and intuitively appealing
source of information to inform policy makers and developers of technology.
For example, threshold analysis can help to identify the maximum price that
a government might be willing to pay for a drug. Such information can be
used to inform research and development prior to drug licensing or price set-
ting prior to marketing, but also - and probably currently most frequently
- to inform price negotiations when drugs (or other health care technology)
are considered for reimbursement [22]. We showed that this price could
be under- or overestimated when based on deterministic threshold analysis.
Furthermore, while EVPPI allows for the identification of uncertain input
parameters that impact most on the optimal strategy [2], threshold analy-
sis can single out more precisely at which values of an uncertain parameter
the optimal strategy changes. This could inform the design of new trials to
obtain more information about a particular uncertain parameter. Also, the
threshold parameter value directly informs researchers and decision mak-
ers about the (change in) optimal strategy when a more precise estimate
becomes available for a particular uncertain parameter based on new evi-
dence. We believe that parameter threshold analysis has a wide range of
applications, even beyond the field of health economics.
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However, we recommend caution in instances where the parameter of interest
is a non-influential parameter, i.e. when it has a low EVPPI value. As shown
in our example for DOIcare in the setting of Uganda (WTP = $800, D = 2),
it is possible to obtain a threshold value for a non-influential input parameter
using GAM, but knowing the threshold value may have little consequence
for policy makers, as the 95% CI covers almost the whole range of parameter
values. In general, threshold values will be most relevant for uncertain input
parameters that have an important impact on the optimal strategy of choice,
and although GAM works well, it remains important to carefully interpret
the results. If Bretain is low, we do not recommend the interpretation of the
threshold value and the corresponding 95% CI due to the uncertainty.
In conclusion, we provide a flexible, easy to code, and fast alternative to the
2-level Monte Carlo approach for parameter threshold analysis. The GAM
method provides correct estimates of parameter threshold value(s) when
there is a non-linear relationship between the uncertain input parameter
of interest and the outcome of the health economic model. In this study,
we only considered the threshold value for a single parameter. In the fu-
ture, the GAM-based method could be extended to incorporate more than
one parameter in order to conduct simultaneous multi-parameter threshold
analysis.
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Appendix
A R code: A function to preform GAM and de-
termine the parameter threshold value
#### Probabilistic Threshold analysis ####
## Obtaining the threshold value using GAM
## IMPORTANT: the default values are used in gam()
# Input in the function:
## INB: a dataframe with the INB all D health care
## strategies (D is defined as all strategies -1,
## the latter being the baseline option)
## If D= 1 then INB is a vector
## baseline.name: a vector with the name of the baseline
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## option to which all D health care strategies are
## compared to.
## parameter: a vector containing the values of the
## parameter of interest.
## parameter.name: an optional vector containing the
## name of the parameter for which the analysis
## is performed.
## INB and parameter are obtained from the PSA sample.
# Return:
## threshold value: a list containing the parameter
## threshold values
## result: a list containing the results of GAM and
## the optimal strategy for each value of parameter.
pta<- function(INB, baseline.name, parameter, parameter.name=’’){
# Load the library for gam()
library(mgcv)
# Obtain values for use further downstream
n<-length(parameter)
if(class(INB)==’data.frame’){
D <- ncol(INB)
} else{
D <- 1
}
# Sort the parameter values in ascending order
sort_order <- order(parameter)
sort_parameter<- parameter[sort_order]
# 1) Fit a GAM
if(D==1){
# Use the appropriate settings in gam()
result_gam<-gam(INB~s(parameter, bs=’cr’))
fitted_gam<-fitted(result_gam)
# Sort the fitted values according to the input
sort_fitted_gam<- fitted_gam[sort_order]
colnames(sort_fitted_gam)<-colnames(INB)
} else {
fitted_gam<-data.frame(matrix(NA, nrow=n, ncol=D))
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for (i in 1:D){
# Use the appropriate settings in gam()
result_gam<-gam(INB[,i]~s(parameter, bs=’cr’))
fitted_gam[,i]<-fitted(result_gam)
}
# Sort the fitted values according to the input
sort_fitted_gam<- fitted_gam[sort_order,]
colnames(sort_fitted_gam)<-colnames(INB)
}
# 2) Determine the parameter threshold value(s)
## When INB>0, then option d is cost-effective
## If INB<=0, the baseline option is the best choice.
## Create a vector of length n with only 0
strategies<-cbind(rep(0, times=n), sort_fitted_gam)
# Names of which alternative courses of actions.
if(class(INB)==’data.frame’){
colnames(strategies)<-c(baseline.name, colnames(INB))
} else {
colnames(strategies)<-c(baseline.name, ’alternative’)
}
# For each value of parameter, which alternative course
# of action has the highest expected INB.
best_strategy<-colnames(strategies)[apply(strategies, 1, which.max)]
result<-data.frame(sort_parameter, strategies, best_strategy)
if(parameter.name!=’’){
colnames(result)[1]<-parameter.name
}
#Initialize vector that stores row numbers where
# where change in optimal decision occurs
rownr_result<-NULL
for (i in 2:nrow(result)) {
if(result$best_strategy[i]!=result$best_strategy[i-1]){
3
rownr_result<-c(rownr_result,i)
}
}
if(!is.null(rownr_result)){
threshold<-data.frame(matrix(NA, nrow=length(rownr_result)+1,
ncol=2))
threshold[,1]<-c(NA, (result[rownr_result-1,1]+
result[rownr_result,1])/2)
threshold[,2]<-c(as.character(result[c(rownr_result[1]-1),
ncol(result)]),
# Optimal strategy before threshold
as.character(result[rownr_result,ncol(result)]))
colnames(threshold)<-c(’TV’, ’Strategy’)
} else {
threshold<-paste(’There are no threshold values.’,
result$best_strategy[1], ’is always the best.’)
}
return(list(result=result, threshold=threshold))
}
B Samples values of θi in 2-level Monte Carlo ap-
proach
Table 1 displays the values that were used from the range of values of θi.
For all settings, the same number of values were samples, K = 7.
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Table 1: Values used for θi in the adjusted 2-level Monte Carlo approach
(K=7)
Setting Parameter θ
(k)
i
Nicaragua, WTP = $1000, D=1 CFRhosp 0.037, 0.038, 0.039, 0.040, 0.041, 0.042, 0.043
Pr(hosp) 0.039, 0.040, 0.041, 0.042, 0.043, 0.044, 0.045
DOIcare 10, 12, 14, 16, 18, 20, 22
Nicaragua, WTP = $1000, D = 2 CFRhosp 0.065, 0.066, 0.067, 0.068, 0.069, 0.070, 0.071
Pr(hosp) 0.070, 0.071, 0.072, 0.073, 0.074, 0.075, 0.076
DOIcare 10, 12, 14, 16, 18, 20, 22
Uganda, WTP = $800, D = 2 CFRhosp 0.055, 0.056, 0.057, 0.068, 0.069, 0.070, 0.071
Pr(hosp) 0.058, 0.059, 0.060, 0.061, 0.072, 0.073, 0.074
DOIcare 10, 12, 14, 16, 18, 20, 22
Cambodia, WTP = $100, D = 2 CFRhosp 0.052, 0.053, 0.054, 0.055, 0.079, 0.080, 0.081
Pr(hosp) 0.057, 0.058, 0.059, 0.060, 0.082, 0.083, 0.084
Cambodia, WTP = $8000, D = 2 CFRhosp 0.001, 0.01, 0.03, 0.05, 0.07, 0.085, 0.1
Pr(hosp) 0.01, 0.05, 0.09, 0.13, 0.17, 0.21, 0.25
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C Sensitivity Analysis
In Table 2, we compare the threshold values obtained via different smooth-
ing option in the gam() function. In Table 2 of the main article, we used
cubic regression splines with dimension 20. In Table 2, we use again cubic
regression splines, but now with dimension 10 (default option in R [1]). In
addition, we use thin plate regression splines to obtain the threshold value.
The advantage of using thin plate regression splines is that it is not neces-
sary to specify the number of knots (and thus the dimension), i.e. it is knot
free [2].
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Table 2: A comparison of the parameter threshold values, obtained with GAM, as reported in Table 2 in the main article
with a cubic regression spline with dimension 10 and thin plate splines
.
GAM GAM
Cubic regression splines, L = 10, K = 10000 Thin plate regression splines, K = 10000
θi EVPPI θ
∗
i d
(k∗+1) Timea 95% CI Bretain/B Time
b θ∗i d
(k∗+1) Timea 95% CI Bretain/B Time
b
Nicaragua, WTP = $1000, 1 health care strategy (D = 1; RC15) compared to no vaccination (d0)
CFRhosp 700094 0.037 RC15 0.5 0.034-0.038 1000/1000 166.6 0.036 RC15 1.0 0.034-0.038 996/1000 340.3
Pr(hosp) 1276475 0.041 RC15 0.7 0.040-0.043 1000/1000 164.9 0.041 RC15 1.0 0.040-0.044 881/1000 334.6
DOIcare 0 Nonec RC15 0.5 NA-NA 430/1000 165.1 None RC15 1.0 NA-NA 577/1000 337.3
Nicaragua, WTP = $1000, 2 health care strategies (D = 2; RC5 and RC15) compared to no vaccination (d0)
CFRhosp 1860599 0.065 RC15 0.5 0.059-0.071 998/1000 175.4 0.064 RC15 1.5 0.058-0.074 990/1000 520.4
Pr(hosp) 2665148 0.070 RC15 0.5 0.065-0.074 1000/1000 176.8 0.070 RC15 1.5 0.065-0.074 826/1000 520.9
DOIcare 0 None No vac 0.5 NA-NA 422/1000 182.1 None No vac 1.4 NA-NA 434/1000 526.7
Uganda, WTP = $800, 2 health care strategies (D = 2; RC5 and RC15) compared to no vaccination (d0)
CFRhosp 18451230 0.058 RC5 0.7 0.053-0.061 998/1000 190.6 0.057 RC5 1.8 0.053-0.061 861/1000 559.6
0.072 RC15 0.065-0.080 0.071 RC15 0.066-0.077
Pr(hosp) 25018120 0.060 RC5 0.8 0.058-0.063 1000/1000 200.1 0.060 RC5 1.6 0.056-0.064 812/1000 556.2
0.073 RC15 0.069-0.077 0.072 RC15 0.067-0.075
DOIcare 4256 0.033 RC5 0.6 0.028-0.061 208/1000 194.1 0.033 RC5 1.7 0.028-0.061 332/1000 564.2
Cambodia, WTP = $100, 2 health care strategies (D = 2; RC5 and RC15) compared to no vaccination (d0)
CFRhosp 2788364 0.055 RC5 0.6 0.052-0.064 998/1000 188.6 0.055 RC5 1.5 0.049-0.060 994/1000 590.8
0.079 RC15 0.075-0.089 0.083 RC15 0.078-0.092
Pr(hosp) 4837512 0.060 RC5 0.8 0.058-0.062 1000/1000 191.3 0.060 RC5 1.8 0.058-0.064 972/1000 552.4
0.085 RC15 0.081-0.090 0.084 RC15 0.081-0.088
Cambodia, WTP = $8000, 2 health care strategies (D = 2; RC5 and RC15) compared to no vaccination (d0)
CFRhosp 0 None RC15 0.9 NA-NA 975/1000 213.7 None RC15 1.6 NA-NA 912/1000 562.5
Pr(hosp) 0 None RC15 0.6 NA-NA 651/1000 187.8 0.001 RC15d 2.0 0.0006-0.003 305/1000 565.0
Notation: See Table 2 in the main article. a,b indicate the time needed to perform respectively the method and the bootstrap; c ’None’
indicates that no parameter threshold value was obtained, meaning that the health care strategy with the highest expected INB remains
the same and is denoted under d(k
∗+1); d the optimal strategy before the threshold value was RC5 instead of no vac.
D Bootstrap procedure for non-influential param-
eters
In this section, we elaborate on the observation of low Bretain for non-
influential parameters. For comparison, we again explore the results for the
non-influential parameter DOIcare. In addition, we provide results for the
proportion of typhoid cases infected with an antimicrobial resistant (AMR)
strain (AMR), the burden of AMR cases relative to AMR sensitive cases
(BurdenAMR), and the relative duration illness for patients not seeking
medical care (DOInocare/care). The characteristics of each input parameter
are shown in Table 3.
Table 3: Distributional characteristics of the non-influential input parame-
ters.
Parameter Mean Median 95% CIa Uncertainty distribution
AMR (%) 0.5 0.5 0.02-0.98 Uniform(0, 1)
BurdenAMR 2 2 1-3 Uniform(1, 3)
DOInocare/care 0.5 0.5 0.02-0.98 Uniform(0, 1)
a 95% credible. interval
In the case of non-influential parameters (such as DOIcare in Table 2 of the
main article), the bootstrap samples retained are much lower compared to
influential parameters. Remember that a non-influential parameter will not
affect the optimal decision, and hence there is no threshold value. If Bretain
is low, then in the majority of the bootstrap samples, at least one threshold
value is obtained.
We compared the results from different non-influential input parameters.
Table 4 displays the results from a GAM using cubic splines regression
(L = 20, K = 10000). We observe that EV PPI = 0 defines non-influential
parameters. Defining a parameter as non-influential based on a low EVPPI
value is very arbitrary since for EV PPI > 0 parameter threshold value(s)
are observed (See also Table 2 in the article, DOIcare for Uganda (WTP =
800$, D = 2)). The 95% CI surrounding the threshold value is usually very
wide, rendering the interpretation of the threshold value invaluable. The rea-
son for observing at least one threshold value in the case of non-influential
parameters is that (1) the shape of the GAM is affected by the individual
bootstrap samples and (2) the uncertainty surrounding the health care strat-
egy due to other parameters might determine greatly whether the health care
strategy come forward as the most optimal strategy or not. Therefore, we
do not recommend to interpret threshold values and corresponding 95%CI
when Bretain is low.
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Table 4: Results from GAM for non-influential parameters
GAM
Cubic regression splines, L = 20, K = 10000
θi EVPPI θ
∗
i d
(k∗+1) Timea 95% CI Bretain/B Time
b
Nicaragua, WTP = $1000, 1 health care strategy (D = 1; RC15)
compared to no vaccination (d0)
AMR 0 None RC15 0.7 NA-NA 675/1000 185.8
BurdenAMR 65 1.010 RC15 0.6 1.004-1.213 419/1000 183.8
DOInocare/care 0 None RC15 0.5 NA-NA 843/1000 184.0
Nicaragua, WTP = $1000, 2 health care strategies (D = 2; RC5 and RC15)
compared to no vaccination (d0)
AMR 194461 0.667 RC15 0.6 0.514-0.808 192/1000 243.5
BurdenAMR 390545 2.230 RC15 1.0 1.863-2.589 614/1000 238.5
DOInocare/care 0 None No vac 0.7 NA-NA 77/1000 202.5
Uganda, WTP = $800, 2 health care strategies (D = 2; RC5 and RC15)
compared to no vaccination (d0)
AMR 1375066 0.076 No vacd 0.6 0.009-0.474 146/1000 204.9
0.463 RC5 0.325-0.772
0.779 RC15 0.585-0.978
BurdenAMR 3255705 1.827 RC5 0.6 1.567-2.066 208/1000 202.2
2.440 RC15 2.262-2.665
DOInocare/care 39382 0.806 No vac
d 0.6 0.155-0.844 18/1000 202.8
0.892 RC5 0.279-0.966
Notation: See Table 2 in the main article. a,b indicate the time needed to perform
respectively the method and the bootstrap; c ’None’ indicates that no parameter
threshold value was obtained, meaning that the health care strategy with the highest
expected INB remains the same and is denoted under d(k
∗+1); d the optimal strategy
before the threshold value was RC5.
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